These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 23968993)

  • 21. Quantitative analysis to guide orphan drug development.
    Lesko LJ
    Clin Pharmacol Ther; 2012 Aug; 92(2):258-61. PubMed ID: 22739138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Orphan drugs: drugs for rare diseases].
    Schenk M
    Dtsch Med Wochenschr; 2010 May; 135(18):p17. PubMed ID: 20455291
    [No Abstract]   [Full Text] [Related]  

  • 23. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products.
    Dear JW; Lilitkarntakul P; Webb DJ
    Br J Clin Pharmacol; 2006 Sep; 62(3):264-71. PubMed ID: 16934041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The European rare diseases therapeutic initiative.
    Fischer A; Borensztein P; Roussel C
    PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Companies look for profit in orphan drugs.
    Thompson CA
    Am J Health Syst Pharm; 2010 Nov; 67(22):1892, 1895-6. PubMed ID: 21048203
    [No Abstract]   [Full Text] [Related]  

  • 26. Pfizer explores rare disease path.
    Shaffer C
    Nat Biotechnol; 2010 Sep; 28(9):881-2. PubMed ID: 20829809
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug labels: a flawed source of data for studying orphan drug approvals.
    Kesselheim AS; Avorn J
    Clin Pharmacol Ther; 2012 Dec; 92(6):694; author reply 695. PubMed ID: 23073207
    [No Abstract]   [Full Text] [Related]  

  • 28. Alternative business models for drug discovery.
    Bunin BA; Ekins S
    Drug Discov Today; 2011 Aug; 16(15-16):643-5. PubMed ID: 21745585
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug discovery: new models for industry-academic partnerships.
    Tralau-Stewart CJ; Wyatt CA; Kleyn DE; Ayad A
    Drug Discov Today; 2009 Jan; 14(1-2):95-101. PubMed ID: 18992364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Orphan drugs--medications for patients with rare diseases].
    Thielke D; Thyssen JP; Hansen BJ
    Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rare diseases and effective treatments: are we delivering?
    Luzzatto L; Hollak CE; Cox TM; Schieppati A; Licht C; Kääriäinen H; Merlini G; Schaefer F; Simoens S; Pani L; Garattini S; Remuzzi G
    Lancet; 2015 Feb; 385(9970):750-2. PubMed ID: 25752159
    [No Abstract]   [Full Text] [Related]  

  • 32. Rare diseases, orphan drugs, and orphaned patients.
    Scheindlin S
    Mol Interv; 2006 Aug; 6(4):186-91. PubMed ID: 16960139
    [No Abstract]   [Full Text] [Related]  

  • 33. What is the most important approach in current drug discovery: doing the right things or doing things right?
    Elebring T; Gill A; Plowright AT
    Drug Discov Today; 2012 Nov; 17(21-22):1166-9. PubMed ID: 22569181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Orphan Drugs and Their Impact on Pharmaceutical Development.
    Attwood MM; Rask-Andersen M; Schiöth HB
    Trends Pharmacol Sci; 2018 Jun; 39(6):525-535. PubMed ID: 29779531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lucrative niches: how drugs for rare diseases became lifeline for companies.
    Anand G
    Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
    [No Abstract]   [Full Text] [Related]  

  • 36. Orphan economics: the downside of supplyside pharmacology.
    Samson K
    Ann Neurol; 2008 Sep; 64(3):A13-6. PubMed ID: 18825669
    [No Abstract]   [Full Text] [Related]  

  • 37. [Conference 1. An economic observatory for orphan drugs: myth or reality?].
    Duguet C; Ferry A
    Med Sci (Paris); 2014 Apr; 30 Spe(1):21-3. PubMed ID: 24755173
    [No Abstract]   [Full Text] [Related]  

  • 38. PPPs succeeding in tackling neglected diseases.
    Frantz S
    Nat Rev Drug Discov; 2005 Oct; 4(10):796-7. PubMed ID: 16237841
    [No Abstract]   [Full Text] [Related]  

  • 39. Orphan drug legislation: lessons for neglected tropical diseases.
    Villa S; Compagni A; Reich MR
    Int J Health Plann Manage; 2009; 24(1):27-42. PubMed ID: 18435430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Should off-label drug use be off-the-table?
    Rivkees SA
    J Pediatr Endocrinol Metab; 2007 Feb; 20(2):171-2. PubMed ID: 17396432
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.